A Phase 1 interventional study of LY3839056 IV and Placebo IV in Healthy Participants, sponsored by Eli Lilly and Company. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to see if LY3839056 is safe and well tolerated when given as a single dose into a vein intravenous (IV) or under the skin subcutaneous (SC) in healthy participants. The study will also measure how much LY3839056 gets into the blood and how long it takes the body to remove it. The study will last up to 17 weeks and includes a stay of about 6 days at the clinical research unit.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive LY3839056 Intravenously
Drug: LY3839056 IV
Participants will receive LY3839056 Intravenously
Drug: LY3839056 IV
Participants will receive LY3839056 Intravenously
Drug: LY3839056 IV
Participants will receive LY3839056 Intravenously
Drug: LY3839056 IV
Participants will receive LY3839056 Subcutaneously
Drug: LY3839056 SC
Participants will receive LY3839056 Intravenously
Drug: LY3839056 IV
Participants will receive LY3839056 Intravenously
Drug: LY3839056 IV
Participants will receive LY3839056 Subcutaneously
Drug: LY3839056 SC
Participants will receive Placebo Intravenously
Drug: Placebo IV
Participants will receive Placebo Subcutaneously
Drug: Placebo SC
LY3839056 Administered Intravenously
Also known as: LY3839056 Administered IV
Placebo Administered Intravenously
Also known as: Placebo Administered IV
LY3839056 Administered Subcutaneously
Also known as: LY3839056 Administered SC
Placebo Administered Subcutaneously
Also known as: Placebo Administered SC
To evaluate the safety and tolerability of LY3839056 following single-dose administration (IV or SC) in healthy participants.
Frequency of AEs, TEAEs, SAEs, and Discontinuation due to TEAEs.
Time frame: Baseline through Day 85
PK: Cmax
Maximum Observed Concentration (Cmax) of LY3839056 following single SC or IV dose
Time frame: Predose on Day 1 up to Day 85
PK: AUC
Area Under the Concentration Versus Time Curve (AUC) of LY3839056 following single SC or IV dose
Time frame: Predose on Day 1 up to Day 85
PK: t1/2
Half Life (t1/2) of LY3839056 following single SC or IV dose
Time frame: Predose on Day 1 up to Day 85
PK: F%
Bioavailability (F%) of LY3839056 following single SC dose
Time frame: Predose on Day 1 up to Day 85
Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.